Best of ASCO - 2014 Annual Meeting

 

Welcome

Local-Regional Non-Small Cell Lung Cancer

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A comparative safety analysis for durvalumab in patients with locally advanced, unresectable NSCLC: PACIFIC versus pooled durvalumab monotherapy studies.

Scott Joseph Antonia

8556

A deep-learning radiomics model for predicting survival in early-stage non-small cell lung cancer.

Tafadzwa Lawrence Chaunzwa

8528

A gene expression signature to characterize human lung adenocarcinoma cancer stem cells.

Alejandro Herreros-Pomares

e20547

A phase I study of neoadjuvant cisplatin (C), docetaxel (D) and nintedanib (N) for resectable non-small cell lung cancer (NSCLC).

Tina Cascone

8555

A phase I//II study of computed tomography-guided interstitial high-dose-rate brachytherapy in combination with regional positive lymph node intensity-modulated radiotherapy for locally advanced peripheral non-small cell lung cancer.

Li Xiang

e20508

A phase II trial of stereotactic body radiation therapy for operable T1N0M0 non-small cell lung cancer: Japan Clinical Oncology Group (JCOG0403)—Long term follow-up results.

Yasushi Nagata

8512

A real-world observational study to explore clinical characteristics of Chinese patients with T1 non-small cell lung cancer complicated with lymph metastases.

Feng Jiang

e20523

An imaging/biology correlation study between radiomics features and anaplastic lymphoma kinase (ALK) mutational status in a uniform Chinese cohort of locally advanced lung adenocarcinomas.

Meilin Jiang

e20540

Association between certain NSCLC driver mutations and sensitivity markers for chemotherapy or PD-(L)1 inhibition: A large-sample analysis.

Wenhua Liang

8542

Association between hospital volume, treatment patterns, and overall survival (OS) of patients with stage 3A non-small cell lung cancer (NSCLC).

Sri Harsha Tella

8543

Big data for supporting precision medicine in lung cancer patients.

Maria Torrente

e20546

Carboplatin (CBDCA), S-1 and concurrent thoracic radiotherapy (TRT) for elderly patients with locally advanced non-small cell lung cancer (NSCLC): A phase II study.

Seiji Niho

8530

Circulating tumor DNA (ctDNA) as a marker of minimal residual disease (MRD) in localized non-small cell lung carcinoma (NSCLC).

Nicholas I. Simon

8550

Clinical characteristics of patients with lymph skip metastases and prognoses of Chinese patients with pN2 non-small cell lung cancer.

Xin Li

e20524

Clinical relevance of intratumoural immune cell composition in non-small cell lung cancer.

Xuetao Li

8547

Clinical significance and next-generation sequencing of Chinese pulmonary sarcomatoid carcinoma.

Jun Chen

e20553

Comparative evaluation of effectiveness of neoadjuvant chemoimmunotherapy (nPCIT) for non-small cell lung cancer (NSCLC).

Yuri Lazutin

8534

Comparison between the microbiota in lung tumor and adjacent normal tissues in lung cancer patients.

Qixing Mao

e20548

Comparison of clinical characteristics and prognoses of patients with T1 non-small cell lung cancer and small cell lung cancer in a Chinese real-world study.

Xu Jinming

e20527

Comparison of surgeries plus perioperative and postoperative chemotherapies in Chinese pN2 patients with non-small cell lung cancer: A real-world observational study.

Jinbo Zhao

e20535

Co-mutations in surgically resected and EGFR mutated lung adenocarcinoma: A subset analysis of the large prospective cohort study.

Kenji Sawa

e20520

Concept to clinic: An open-innovation crowdsourcing challenge to develop AI-enabled software for lung cancer detection.

Guneet Walia

e20552

Concurrent chemotherapy and radiation versus chemotherapy alone for N3 stage IIIb NSCLC in elderly patients.

Angel Qin

8536

Definitive local therapy for oligo-recurrence in patients with completely resected non-small cell lung cancer.

Haruhisa Matsuguma

8527

Development and validation of a molecule based nomogram to predict relapse in stage I NSCLC.

Qixing Mao

e20544

Differential diagnosis of pulmonary enteric adenocarcinoma (PEAC) with the assistance of next generation sequencing.

Jie Zhang

e20537

Effect of radiation dose escalation on outcomes in patients with N2 stage IIIA NSCLC undergoing induction therapy prior to surgical resection.

Greg Andrew Durm

8513

Effectiveness and safety of lobectomy and sublobar dissection in Chinese elderly patients with non-small cell lung cancer: A real-world observational study.

Zhenrong Zhang

e20522

Effectiveness and safety of systematic and selective lymphadenectomies in Chinese patients with non-small cell lung cancer who received sublobar resection.

Min Zhu

e20534

Efficacy and safety of liposome-paclitaxel and carboplatin based concurrent chemoradiotherapy for locally advanced lung squamous cell carcinoma.

Liming Sheng

e20516

Endogenous arginase 2 as a biomarker for PEGylated arginase 1 treatment in squamous cell lung carcinoma xenograft models.

James C. M. Ho

e20538

Evaluating PD-L1 status and its correlation with clinical features in surgically resected lung adenocarcinoma patients: Comparison of tissue microarrays and whole tissue section.

Hsu-Ching Huang

8548

Final results of RENO study: Randomized phase II of oral vinorelbine or etoposide with cisplatin and chemo-radiation in stage III NSCLC. SLCG 10/02.

Mariano Provencio-Pulla

e20521

Genome-wide identification and characterization of aberrant tRNA-derived RNA fragments in non-small cell lung cancer.

Lin Yang

e20539

Genome-wide sequencing for early stage lung cancer detection from plasma cell-free DNA (cfDNA): The Circulating Cancer Genome Atlas (CCGA) study.

Geoffrey R. Oxnard

LBA8501

Geriatric assessment to predict toxicity in elderly patients with unresectable locally advanced non-small-cell lung cancer treated with concurrent chemoradiotherapy.

Ernest Nadal

8557

Hypercalcemia in malignancy: An inpatient analysis.

Divya Asti

e20517

Impact of a comprehensive geriatric assessment to manage elderly patients with locally advanced non-small-cell lung cancers: An open phase II study using concurrent cisplatin - oral vinorelbine and radiotherapy (GFPC 08-06).

Hervé Le Caer

e20513

Impact of corticosteroid administration on outcomes following stereotactic ablative radiotherapy for non-small cell lung cancer.

Hongqi LI

e20518

Impact of somatic mutations on recurrence free survival (RFS) and overall survival (OS) for resected non-small cell lung cancer (NSCLC): results from the Japan Molecular Epidemiology for lung cancer study (JME).

Akihiro Tamiya

8549

Initial results of the phase ib/II, I-START trial: Isotoxic accelerated radiotherapy for the treatment of stage II-IIIb NSCLC.

Jason Francis Lester

e20551

Insurance disparity in cause-specific mortalities: A SEER study on early stage, non-elderly NSCLC cancer survivors.

Changchuan Jiang

8538

Long-term outcomes after sublobar resection for clinical stage IA lung adenocarcinoma meeting node-negative criteria defined by HRCT and FDG-PET/CT.

Yasuhiro Tsutani

8554

Long-term results of a phase I/II trial of nelfinavir with concurrent chemoradiotherapy for locally advanced non-small cell lung cancer.

Ramesh Rengan

8552

Long-term survival after salvage SBRT for recurrent or secondary non-small cell lung cancer after prior surgery or radiation therapy.

Chunyu He

8558

Long-term survival comparison of stereotactic radiotherapy versus surgery for elderly patients with clinical stage T1-T2 non-small cell lung cancer.

Feng-Ming Spring Kong

8511

Microwave ablation plus recombinant human endostatin (endostar) versus microwave ablation alone in inoperable stage I non small cell lung cancer.

Min Meng

8551

Multimodal treatment in operable stage III non-small cell lung cancer using the new TNM staging classification version 8: Long term results of a pooled analysis of three SAKK trials.

Martin Frueh

8531

NanoPac inhalation treatment of NSCLC in a nude rat orthotopic lung cancer model.

Gere Dizerega

8535

Neoadjuvant atezolizumab + chemotherapy in resectable non-small cell lung cancer (NSCLC).

Catherine A. Shu

8532

Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Initial results from a multicenter study (LCMC3).

Valerie W. Rusch

8541

Neutrophil to lymphocyte ratio (NLR) as a useful prognostic marker for survival in patients with locally advanced (stage III) non-small cell lung cancer (NSCLC).

Ali Tahir

e20511

New generation of cancer stem cells inhibitors in non-small cell lung cancer.

Héctor Amado Labrador

e20545

NORA trial (GECP 15/02): First efficacy results of the Spanish Lung Cancer Group (SLCG) phase II trial of concurrent chemo-radiotherapy (CT-RT) with cisplatin (P) plus metronomic oral vinorelbine (mOV) for unresectable locally advanced non-small cell lung cancer (LA-NSCLC).

Dolores Isla

8537

PD-L1 expression in patients with unresectable stage III non-small cell lung cancer receiving chemoradiotherapy.

Nobuaki Mamesaya

e20530

Phase II trial of atezolizumab before and after definitive chemoradiation for unresectable stage III NSCLC.

Helen J. Ross

TPS8585

Phase II trial of concurrent chemoradiation with consolidation pembrolizumab in patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179.

Greg Andrew Durm

8500

Pragmatic study of a lymph node (LN) collection kit for non-small cell lung cancer (NSCLC) resection.

Raymond U. Osarogiagbon

8502

Prognostic factors for survival in locally advanced NSCLC treated with concurrent chemo- radiation: An institutional analysis.

Sowmini Medavaram

e20512

Prognostic sıgnificance of PD-L1 in stage II/III non-small cell lung cancer.

Deniz Tural

e20532

Progression-free survival (PFS) and cardiac-toxicity-adjusted-PFS (CTA-PFS) as predictors of overall survival (OS) in locally advanced non-small cell lung cancers (LA-NSCLC) treated with concurrent chemoradiation (CCRT): A secondary analysis of NRG Oncology RTOG 0617.

Chen Hu

8539

Randomized, double-blind phase 3 study evaluating neoadjuvant platinum-based chemotherapy with perioperative pembrolizumab or placebo in resectable stage IIB or IIIA NSCLC: KEYNOTE-671.

Hiran C. Fernando

TPS8583

Relationship between pre-diagnosis tumor board and time interval from imaging to staging in lung cancer.

Prashanth Thalanayar Muthukrishnan

e20536

Routine use of a modest next generation sequencing panel provides additional clinically useful data beyond single gene testing in non-small cell lung cancer and is fit for purpose as a clinical assay: Collated data from a single molecular diagnostic laboratory.

David Allan Moore

8540

Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-RT regimen in unresectable locally advanced NSCLC: The ETOP NICOLAS phase II trial.

Solange Peters

8510

SAKK 16/14: Anti-PD-L1 antibody durvalumab (MEDI4736) in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)—A multicenter single-arm phase II trial.

Sacha Rothschild

TPS8584

Significance of aromatase-estrogen receptor axis in EGFR status of lung adenocarcinoma.

Kazumi Tanaka

8553

Surgical treatments of Chinese patients with lung malignant tumors.

Hu Liao

e20525

Survival in right-sided versus left-sided stage IB-IIIA non-small cell lung cancer patients.

Ziping Wang

e20509

Survival in the population-based Mid-South Quality of Surgical Resection (MSQSR) Cohort.

Matthew Smeltzer

e20550

The ASCENT trial: A phase II study of neoadjuvant afatinib, chemoradiation and surgery for stage III EGFR mutation-positive NSCLC.

Lecia V. Sequist

8544

The effect of prior smoking history on the molecular profile of EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC).

Hadas Sorotsky

8533

The prognostic significance of ATRX in pulmonary carcinoid tumors.

Hao Xie

e20543

Time to treatment and survival in veterans with stage I-IIIA lung cancer eligible for curative intent therapy.

Duc Ha

e20519

Trends in non-small cell lung cancer biomarker testing rates in the US and Western Europe from 2014-2017.

Bijal Shah-Manek

e20515

tRNA modification profiles of non-small cell lung cancer (NSCLC).

Rihong Zhai

e20542

Tumor CD47 expression and a high M2/M1 ratio of tumor-associated macrophages as an adverse prognostic factor in resected stage Ⅲa non-small cell lung cancer.

Yan Xu

e20531

Use of QTc-prolonging medications among patients with lung cancer: implications for clinical trials and standard clinical care.

David E. Gerber

e20529

Using deep-learning radiomics to predict lung cancer histology.

Tafadzwa Lawrence Chaunzwa

8545